Keymed Biosciences Inc.

SEHK:2162 Stock Report

Market Cap: HK$11.6b

Keymed Biosciences Balance Sheet Health

Financial Health criteria checks 4/6

Keymed Biosciences has a total shareholder equity of CN¥2.6B and total debt of CN¥719.5M, which brings its debt-to-equity ratio to 27.3%. Its total assets and total liabilities are CN¥3.8B and CN¥1.2B respectively.

Key information

27.3%

Debt to equity ratio

CN¥719.55m

Debt

Interest coverage ration/a
CashCN¥2.58b
EquityCN¥2.64b
Total liabilitiesCN¥1.17b
Total assetsCN¥3.81b

Recent financial health updates

Recent updates

Health Check: How Prudently Does Keymed Biosciences (HKG:2162) Use Debt?

Oct 21
Health Check: How Prudently Does Keymed Biosciences (HKG:2162) Use Debt?

There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump

May 13
There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump

News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat

Apr 03
News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat

Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 31
Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates

A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)

Nov 13
A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)

Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts

Sep 03
Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts

Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher

Mar 21
Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher

Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth

Jun 27
Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth

Financial Position Analysis

Short Term Liabilities: 2162's short term assets (CN¥2.8B) exceed its short term liabilities (CN¥559.7M).

Long Term Liabilities: 2162's short term assets (CN¥2.8B) exceed its long term liabilities (CN¥608.6M).


Debt to Equity History and Analysis

Debt Level: 2162 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 2162's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2162 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 2162 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies